Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OXTR | P30559 | 10/20 | 0.54 |
| ▸ | AVPR1A | P37288 | 9/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25375402 | 0.90 | OXTR (0.52) | OXTRAVPR1AMEN1KMT2AGAA | |
| SCHEMBL25374775 | 0.83 | OXTR (0.56) | OXTRAVPR1AMEN1KMT2AGAA | |
| SCHEMBL20776699 | 0.81 | OXTR (0.53) | OXTRAVPR1AMEN1KMT2A | |
| SCHEMBL25378735 | 0.80 | HDAC1 (0.55) | MEN1KMT2AGAA | |
| SCHEMBL25377496 | 0.76 | OXTR (0.48) | OXTRAVPR1AMEN1KMT2A | |
| SCHEMBL6682858 | 0.74 | LMNA (0.53) | MEN1KMT2A | |
| SCHEMBL20593624 | 0.73 | HDAC6 (0.50) | OXTRAVPR1AMEN1KMT2A | |
| SCHEMBL25377110 | 0.73 | L3MBTL1 (0.46) | OXTRAVPR1AMEN1KMT2AGAA | |
| SCHEMBL1337005 | 0.73 | NPC1 (0.59) | OXTRAVPR1AMEN1KMT2AGAA | |
| SCHEMBL3566149 | 0.73 | MAPT (0.53) | OXTRAVPR1AMEN1KMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250136594-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2025-05-01 | — | — | US | disclosed |
| EP-4469438-A1 | COMPOUNDS AND METHODS OF USE | Tango Therapeutics, Inc. (US) | 2024-12-04 | — | — | EP | disclosed |
| WO-2023146987-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023146987-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250136594-A1 | COMPOUNDS AND METHODS OF USE | CNKSR1, UGT1A1, REV1 | OXTR 1561/4885AVPR1A 161/4885MEN1 521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.